Obesity Management Resources

The AASM Obesity Management Task Force compiled these resources to help equip sleep medicine professionals to manage obesity in patients who have sleep disorders. Obesity management options expanded in December 2024, when the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.  

The task force also compiled obesity management resources for patients, which are available on the Sleep Education website. 

The International Classification of Sleep Disorders (ICSD) describes a variety of associations between obesity and sleep disorders.

  • The major predisposing factor for obstructive sleep apnea (OSA) in adults is excess body weight. In the pediatric population, obesity may be a more important risk factor for OSA in older children and adolescents but is also relevant in younger children.
  • Snoring is a cardinal symptom of OSA. Snoring is most common in adult men and is also linked to obesity. 
  • Obesity hypoventilation syndrome is characterized by obesity and daytime hypercapnia, which worsens during sleep and is often associated with severe arterial oxygen desaturation. The majority of these patients have comorbid OSA.
  • Epidemiological studies have shown that obesity is common in narcolepsy type 1. Around disease onset, an unexplained increase in body weight is often observed, particularly when disease onset is more acute, as is often the case in children. 
  • Night shift work is associated with obesity; women are affected more than men. 
  • Adverse health consequences of sleep-related eating disorder (SRED) include obesity (including morbid obesity resulting in bariatric surgery). SRED may complicate the postoperative course of patients undergoing bariatric surgery.
  • The most common symptoms of sleep-related gastroesophageal reflux are heartburn and regurgitation, and predictors of heartburn during sleep include the presence of abdominal obesity. 
  • Truncal-abdominal obesity may further contribute to the likelihood of sleep-related myocardial ischemia/infarction.

Several AASM practice standards include guidance related to obesity.

Featured

Canadian adult obesity clinical practice guideline
Developed by Obesity Canada and the Canadian Association of Bariatric Physicians and Surgeons, this guideline contains 19 open-source chapters that will be updated as new evidence arises. Most recently, the chapter on pharmacotherapy in obesity management was updated in 2025 to reflect the latest research and treatment options.

Year Title Organization Link
2026 Use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults World Health Organization View guideline
2025 Management of adult overweight and obesity U.S. Department of Veterans Affairs and Department of Defense View guideline
2025 Canadian adult obesity clinical practice guideline Obesity Canada and the Canadian Association of Bariatric Physicians and Surgeons View guideline
2025 Canadian pediatric obesity clinical practice guideline Obesity Canada View guideline
2023 Evaluation and treatment of children and adolescents with obesity American Academy of Pediatrics View guideline
2022 Pharmacological interventions for adults with obesity American Gastroenterological Association View guideline
2021 Referral of adults with obstructive sleep apnea for surgical consultation American Academy of Sleep Medicine View guideline
2018 The role of weight management in the treatment of adult obstructive sleep apnea American Thoracic Society View guideline
2018 Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults U.S. Preventive Services Task Force View guideline
2016 Comprehensive clinical practice guidelines for medical care of patients with obesity American Association of Clinical Endocrinologists and American College of Endocrinology View guideline
2015 European guidelines for obesity management in adults Obesity Facts View guideline
2013 Guideline for the management of overweight and obesity in adults American College of Cardiology, American Heart Association, and The Obesity Society View guideline

Featured

Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease – 2025 update
Published in 2025 by the American Association of Clinical Endocrinology, this consensus statement provides visual guidance in graphic algorithms to assist health care professionals and patients in shared decision making to improve care and achieve health goals.

Year Title Organization Link
2025 Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease – 2025 update American Association of Clinical Endocrinology View statement
2025 Nutritional priorities to support GLP‐1 therapy for obesity American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society View statement
2025 Obesity management in primary care: A joint clinical perspective and expert review Obesity Medicine Association and American College of Osteopathic Family Physicians View statement
2025 Definition and diagnostic criteria of clinical obesity The Lancet Diabetes & Endocrinology Commission View statement
2025 Dietary guidelines for Americans U.S. Department of Health and Human Services and U.S. Department of Agriculture View statement
2023 Definitions and clinical practice guidelines for obesity management — an international Delphi study International Federation for the Surgery and Other Therapies for Obesity View statement
2020 Waist circumference as a vital sign in clinical practice International Atherosclerosis Society and International Chair on Cardiometabolic Risk View statement
2018 Physical activity guidelines for Americans, 2nd edition U.S. Department of Health and Human Services View statement
2017 Adiposity-based chronic disease as a new diagnostic term American Association of Clinical Endocrinology and American College of Endocrinology View statement

Featured

Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review
Published in 2025 in the Journal of Clinical Sleep Medicine, this narrative review concludes that SGLT2 inhibitors, GLP-1 receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnea index and weight.

Year Title Journal Link
2025 Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review Journal of Clinical Sleep Medicine View review
2025 Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea Current Opinion in Pulmonary Medicine View review
2025 Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus Journal of Translational Medicine View review
2025 Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions Frontiers in Neurology View review
2025 Obstructive sleep apnea: An evolving therapeutic landscape with an emerging role for incretin-based therapies Advances in Therapy View review
2025 Emerging pharmacotherapies for obesity: A systematic review Pharmacological Reviews View review
2025 Obesity and sleep disorders: A bidirectional relationship Nutrition, Metabolism and Cardiovascular Diseases View review
2025 The integration of lifestyle modification advice and diet and physical exercise interventions: Cornerstones in the management of obesity with incretin mimetics Obesity Facts View review
2025 Effectiveness of behavioural and psychological interventions for managing obesity in children and adolescents Pediatric Obesity View review
2024 The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea Obesity Reviews View review
2024 Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments Sleep Medicine Reviews View review
2024 Effectiveness of surgical interventions for managing obesity in children and adolescents Pediatric Obesity View review
2024 Effectiveness of pharmacological interventions for managing obesity in children and adolescents Pediatric Obesity View review
2023 Sleep apnea, obesity, and diabetes — an intertwined trio Current Diabetes Reports View review
2023 Obesity management in adults JAMA View review
2023 Dietary and lifestyle risk factors of obesity among young adults Current Nutrition Reports View review
2022 Are individual or group interventions more effective for long-term weight loss in adults with obesity? Clinical Obesity View review
2021 Fear-related barriers to physical activity among adults with overweight and obesity Obesity Reviews View review
2019 Weight management in young adults: Systematic review of electronic health intervention components and outcomes Journal of Medical Internet Research View review

Featured

Tirzepatide for the treatment of obstructive sleep apnea and obesity
Published in 2024 in the New England Journal of Medicine, these two phase 3, double-blind, randomized, controlled trials found that participants who received tirzepatide had a clinically meaningful change in sleep-disordered breathing and alleviation of perceived sleep disturbance and sleep-related impairment, as well as reductions in common obstructive sleep apnea-related cardiovascular risk factors.

Title Journal Link
Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide Journal of Clinical Sleep Medicine View article
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial Nature Medicine View article
Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity Sleep Medicine View article
Clinical impact of tirzepatide on patients with OSA and obesity CHEST View article
Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score matched study Diabetes Research and Clinical Practice View article
Tirzepatide and semaglutide for the treatment of obstructive sleep apnea and obesity: a retrospective analysis Medical Research Archives View article
Tirzepatide for the treatment of obstructive sleep apnea and obesity New England Journal of Medicine View article
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial Contemporary Clinical Trials View article

Featured

Obesity Education Hub
Developed by Obesity Canada, the Obesity Education Hub offers the tools, strategies, and clinical insights that health care professionals need to confidently support people living with obesity.

Year Title Source Link
2026 Obesity Education Hub Obesity Canada View resource
2026 Obesity resources for healthcare professionals Obesity Canada View resource
2026 Obesity resource library Obesity Action Coalition View resource
2026 Obesity medicine education Obesity Medicine Association View resource
2026 Obesity education The Obesity Society View resource
2026 Resources for healthcare professionals American Society for Metabolic and Bariatric Surgery View resource
2026 Obesity medicine exam eligibility and requirements American Board of Obesity Medicine View resource
2025 Managing adverse effects of incretin-based medications for obesity JAMA View resource
2025 Talk to your patients and clients about healthy eating routines Office of Disease Prevention and Health Promotion View resource
2025 Zepbound® prior authorization resource guide Lilly View resource
2025 Understanding weight stigma and strategies to improve patient care (VIDEO) Uconn Rudd Center and Lilly View resource
2025 Integrating diet and physical activity when prescribing GLP-1s — lifestyle factors remain crucial JAMA Internal Medicine View resource
2023 Ways to reduce weight stigma in clinician-patient communication Uconn Rudd Center and Lilly View resource
2023 Approach the patient with obstructive sleep apnea and obesity Journal of Clinical Endocrinology & Metabolism View resource
2022 The link between obesity and obstructive sleep apnea American Academy of Sleep Medicine View resource
2020 Reducing stigma when talking to patients about weight Uconn Rudd Center for Food Policy and Health View resource
2020 Weight can’t wait: Guide for the management of obesity in the primary care setting Milken Institute School of Public Health The George Washington University View resource
2014 Why weight? A guide to discussing obesity & health with your patients STOP Obesity Alliance View resource
2012 STOP-Bang Questionnaire University of Toronto View resource

Updated March 23, 2026